EGFR and glioblastoma: Therefore, taken together, these results suggest that expression of EGFRvIII occurs in patients with GBM and that this biomarker may be a good candidate for targeted therapy with various types of HER inhibitors, including anti-EGFR, anti-EGFRvIII antibodies, the EGFRvIII T cell bispecific antibody, the anti-EGFRvIII antibody–drug conjugate, and CAR-T cells [94,97,98,99].